PleoPharma
June 23, 2026
Theater 4
Type: Company Presentation
Focus Area:
Other
PleoPharma, Inc. is a clinical stage development company in the neuropsych and addiction space focused on finding solutions for people suffering from cannabis addiction and other cannabis related health problems. PleoPharma’s lead asset, PP-01, is entering Phase 3 clinical trials and is being developed as the first FDA approved treatment of Cannabis Withdrawal Syndrome in people with Cannabis Use Disorder.
Company HQ City:
Phoenixville
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
2019
Lead Product in Development:
PP-01, for Cannabis WIthdrawal Symptoms in patients with Cannabis Use Disorder
CEO
Ginger Constantine
Development Phase of Lead Product
Phase III
When you expect your next catalyst update?
Q4 2027
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}